114 related articles for article (PubMed ID: 30747224)
1. miRNA‑135a regulates Hut78 cell proliferation via the GATA‑3/TOX signaling pathway.
Wei H; Liu R; Guo X; Zhou Y; Sun B; Wang J
Mol Med Rep; 2019 Mar; 19(3):2361-2367. PubMed ID: 30747224
[TBL] [Abstract][Full Text] [Related]
2. Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.
Mehdi SJ; Moerman-Herzog A; Wong HK
BMC Cancer; 2021 May; 21(1):492. PubMed ID: 33941102
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
[TBL] [Abstract][Full Text] [Related]
4. TOX expression and role in CTCL.
McGirt LY; Degesys CA; Johnson VE; Zic JA; Zwerner JP; Eischen CM
J Eur Acad Dermatol Venereol; 2016 Sep; 30(9):1497-502. PubMed ID: 27345620
[TBL] [Abstract][Full Text] [Related]
5. Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma.
Huang Y; Su MW; Jiang X; Zhou Y
Blood; 2015 Feb; 125(9):1435-43. PubMed ID: 25548321
[TBL] [Abstract][Full Text] [Related]
6. miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.
McGirt LY; Adams CM; Baerenwald DA; Zwerner JP; Zic JA; Eischen CM
J Invest Dermatol; 2014 Apr; 134(4):1101-1107. PubMed ID: 24304814
[TBL] [Abstract][Full Text] [Related]
7. Exogenous expression of SAMHD1 inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma-derived HuT78 cells.
Kodigepalli KM; Li M; Liu SL; Wu L
Cell Cycle; 2017 Jan; 16(2):179-188. PubMed ID: 27929746
[TBL] [Abstract][Full Text] [Related]
8. Cooperation of Gata3, c-Myc and Notch in malignant transformation of double positive thymocytes.
van Hamburg JP; de Bruijn MJ; Dingjan GM; Beverloo HB; Diepstraten H; Ling KW; Hendriks RW
Mol Immunol; 2008 Jun; 45(11):3085-95. PubMed ID: 18471881
[TBL] [Abstract][Full Text] [Related]
9. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
Xia L; Wu L; Xia H; Bao J; Li Q; Chen X; Xia R
Cell Cycle; 2019 Jul; 18(14):1635-1645. PubMed ID: 31213131
[TBL] [Abstract][Full Text] [Related]
10. t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5.
Ehrentraut S; Nagel S; Scherr ME; Schneider B; Quentmeier H; Geffers R; Kaufmann M; Meyer C; Prochorec-Sobieszek M; Ketterling RP; Knudson RA; Feldman AL; Kadin ME; Drexler HG; MacLeod RA
PLoS One; 2013; 8(1):e53767. PubMed ID: 23372669
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-455-3p mediates GATA3 tumor suppression in mammary epithelial cells by inhibiting TGF-β signaling.
Zeng Y; Gao T; Huang W; Yang Y; Qiu R; Hou Y; Yu W; Leng S; Feng D; Liu W; Teng X; Yu H; Wang Y
J Biol Chem; 2019 Oct; 294(43):15808-15825. PubMed ID: 31492753
[TBL] [Abstract][Full Text] [Related]
12. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
13. TOX expression in cutaneous B-cell lymphomas.
Schrader AM; Jansen PM; Willemze R
Arch Dermatol Res; 2016 Aug; 308(6):423-7. PubMed ID: 27180090
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
15. LOC285194 inhibits proliferation of human keratinocytes through regulating miR-616/GATA3 pathway.
Lin J; Fang Y; Tao M; Ma L; Cao Y; Li Y; Ji C; Yang J; Yang X
Mol Cell Probes; 2020 Oct; 53():101598. PubMed ID: 32439362
[TBL] [Abstract][Full Text] [Related]
16. Computer-Aided Discovery of Small Molecule Inhibitors of Thymocyte Selection-Associated High Mobility Group Box Protein (TOX) as Potential Therapeutics for Cutaneous T-Cell Lymphomas.
Agrawal V; Su M; Huang Y; Hsing M; Cherkasov A; Zhou Y
Molecules; 2019 Sep; 24(19):. PubMed ID: 31554191
[TBL] [Abstract][Full Text] [Related]
17. TOX expression in cutaneous T-cell lymphomas: an adjunctive diagnostic marker that is not tumour specific and not restricted to the CD4(+) CD8(-) phenotype.
Schrader AM; Jansen PM; Willemze R
Br J Dermatol; 2016 Aug; 175(2):382-6. PubMed ID: 26931394
[TBL] [Abstract][Full Text] [Related]
18. NLRP3 Regulates IL-4 Expression in TOX
Huanosta-Murillo E; Alcántara-Hernández M; Hernández-Rico B; Victoria-Acosta G; Miranda-Cruz P; Domínguez-Gómez MA; Jurado-Santacruz F; Patiño-López G; Pérez-Koldenkova V; Palma-Guzmán A; Licona-Limón P; Fuentes-Pananá EM; Lemini-López A; Bonifaz LC
Front Immunol; 2021; 12():668369. PubMed ID: 34220814
[TBL] [Abstract][Full Text] [Related]
19. Intranasal Administration of Lentiviral miR-135a Regulates Mast Cell and Allergen-Induced Inflammation by Targeting GATA-3.
Deng YQ; Yang YQ; Wang SB; Li F; Liu MZ; Hua QQ; Tao ZZ
PLoS One; 2015; 10(9):e0139322. PubMed ID: 26418311
[TBL] [Abstract][Full Text] [Related]
20. Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma.
Mishra A; La Perle K; Kwiatkowski S; Sullivan LA; Sams GH; Johns J; Curphey DP; Wen J; McConnell K; Qi J; Wong H; Russo G; Zhang J; Marcucci G; Bradner JE; Porcu P; Caligiuri MA
Cancer Discov; 2016 Sep; 6(9):986-1005. PubMed ID: 27422033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
